Kwon Seungwon, Jung Woo-Sang, Yang Seungbo, Jin Chul, Cho Seung-Yeon, Park Seong-Uk, Moon Sang-Kwan, Park Jung-Mi, Ko Chang-Nam, Cho Ki-Ho, Park Min-Jeong
Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Evid Based Complement Alternat Med. 2018 Oct 10;2018:8042198. doi: 10.1155/2018/8042198. eCollection 2018.
Anticoagulant therapy is used to reduce the risk of thromboembolic events in patients with atrial fibrillation. Warfarin has been the traditional anticoagulant but is difficult to use because of its narrow therapeutic window. Recently, newer oral anticoagulants (NOACs) have been developed. However, bleeding continues to be a significant complication. The objective of this study was to assess the safety of acupuncture in patients taking NOACs. The medical records in the Stroke Center at Kyung Hee University Korean Medicine Hospital were retrospectively reviewed to identify patients who had received acupuncture between January 2017 and September 2017. The patients were divided into groups according to whether they were taking an NOAC, an antiplatelet agent, or no anticoagulant therapy. Bleeding-related side effects that occurred immediately after removal of acupuncture needles were recorded. Three hundred and sixteen patients underwent 10,177 acupuncture sessions during the study period. Microbleeding (bleeding that ceased within 30 s) occurred at a rate of 3.9% in the NOAC group, 5.6% in the antiplatelet group, and 5.1% in the control group. There were no between-group differences in the microbleeding rate. No serious adverse events, including major bleeding, were detected. These findings indicate that acupuncture is safe in patients taking NOACs.
抗凝治疗用于降低心房颤动患者发生血栓栓塞事件的风险。华法林一直是传统的抗凝剂，但由于其治疗窗狭窄而难以使用。最近，新型口服抗凝剂（NOACs）已被开发出来。然而，出血仍然是一个严重的并发症。本研究的目的是评估针刺治疗对服用NOACs患者的安全性。对庆熙大学韩医医院卒中中心2017年1月至2017年9月期间接受针刺治疗的患者的病历进行回顾性分析，以确定这些患者。根据患者是否服用NOACs、抗血小板药物或未接受抗凝治疗将其分组。记录针刺针拔出后立即出现的与出血相关的副作用。在研究期间，316名患者接受了10177次针刺治疗。NOAC组微出血（30秒内停止的出血）发生率为3.9%，抗血小板组为5.6%，对照组为5.1%。微出血率在组间无差异。未检测到包括大出血在内的严重不良事件。这些结果表明，针刺治疗对服用NOACs的患者是安全的。
